{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:17:40Z","timestamp":1792783060437,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,24]],"date-time":"2020-10-24T00:00:00Z","timestamp":1603497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,24]],"date-time":"2020-10-24T00:00:00Z","timestamp":1603497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of Shizuoka academic research grant","id":[{"id":"https:\/\/ror.org\/04rvw0k47","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s00280-020-04177-y","type":"journal-article","created":{"date-parts":[[2020,10,24]],"date-time":"2020-10-24T12:02:43Z","timestamp":1603540963000},"page":"73-83","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Analysis of pharmacogenomic factors for chemotherapy-induced nausea and vomiting in patients with breast cancer receiving doxorubicin and cyclophosphamide chemotherapy"],"prefix":"10.1007","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8894-2841","authenticated-orcid":false,"given":"Daiki","family":"Tsuji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Kawasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-I. L.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Nakamichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Sahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Makuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Yokoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiro","family":"Miyagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiko","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,24]]},"reference":[{"key":"4177_CR1","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1007\/s00520-012-1448-1","volume":"20","author":"P Fern\u00e1ndez-Ortega","year":"2012","unstructured":"Fern\u00e1ndez-Ortega P, Caloto MT, Chirveches E, Marquilles R, Francisco JS, Quesada A et al (2012) Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients\u2019 quality of life. Support Care Cancer 20:3141\u20133148. https:\/\/doi.org\/10.1007\/s00520-012-1448-1","journal-title":"Support Care Cancer"},{"issue":"24","key":"4177_CR2","doi-asserted-by":"publisher","first-page":"4472","DOI":"10.1200\/JCO.2006.05.6382","volume":"20","author":"B Bloechl-Daum","year":"2006","unstructured":"Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J (2006) Delayed nausea and vomiting continue to reduce patients\u2019 quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 20(24):4472\u20134478. https:\/\/doi.org\/10.1200\/JCO.2006.05.6382","journal-title":"J Clin Oncol"},{"key":"4177_CR3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s10549-013-2727-3","volume":"142","author":"I Kuchuk","year":"2013","unstructured":"Kuchuk I, Bouganim N, Beusterien K, Grinspan J, Vandermeer L, Gertler S et al (2013) Preference weights for chemotherapy side effects from the perspective of women with breast cancer. Breast Cancer Res Treat 142:101\u2013107. https:\/\/doi.org\/10.1007\/s10549-013-2727-3","journal-title":"Breast Cancer Res Treat"},{"key":"4177_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-015-0852-1","volume":"21","author":"H Takeuchi","year":"2016","unstructured":"Takeuchi H, Saeki T, Aiba K, Tamura K, Aogi K, Eguchi K et al (2016) Japanese Society of Clinical Oncology clinical practice guidelines 2010 for antiemesis in oncology: executive summary. Int J Clin Oncol 21:1\u201312. https:\/\/doi.org\/10.1007\/s10147-015-0852-1","journal-title":"Int J Clin Oncol"},{"key":"4177_CR5","doi-asserted-by":"publisher","first-page":"v119","DOI":"10.1093\/annonc\/mdw270","volume":"27","author":"F Roila","year":"2016","unstructured":"Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E et al (2016) 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 27:v119\u2013v133. https:\/\/doi.org\/10.1093\/annonc\/mdw270","journal-title":"Ann Oncol"},{"key":"4177_CR6","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1200\/JCO.2017.74.4789","volume":"35","author":"PJ Hesketh","year":"2017","unstructured":"Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA et al (2017) Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 35:3240\u20133261. https:\/\/doi.org\/10.1200\/JCO.2017.74.4789","journal-title":"J Clin Oncol"},{"key":"4177_CR7","unstructured":"David S. Ettinger, Berger MJ, Aston J, Barbour S, Bergsbaken J, Brandt D, et al (2019) NCCN Guidelines Version 2. Antiemesis. https:\/\/www.nccn.org\/store\/login\/login.aspx?ReturnURL=https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf. Accessed 19 July 2020"},{"key":"4177_CR8","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1093\/annonc\/mdh110","volume":"15","author":"A Ihbe-Heffinger","year":"2004","unstructured":"Ihbe-Heffinger A, Ehlken B, Bernard R, Berger K, Peschel C, Eichler HG et al (2004) The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Ann Oncol 15:526\u2013536. https:\/\/doi.org\/10.1093\/annonc\/mdh110","journal-title":"Ann Oncol"},{"key":"4177_CR9","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1002\/cncr.20230","volume":"100","author":"SM Grunberg","year":"2004","unstructured":"Grunberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G et al (2004) Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 100:2261\u20132268. https:\/\/doi.org\/10.1002\/cncr.20230","journal-title":"Cancer"},{"key":"4177_CR10","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1007\/s00520-018-4403-y","volume":"27","author":"D Tsuji","year":"2019","unstructured":"Tsuji D, Suzuki K, Kawasaki Y, Goto K, Matsui R, Seki N et al (2019) Risk factors associated with chemotherapy-induced nausea and vomiting in the triplet antiemetic regimen including palonosetron or granisetron for cisplatin-based chemotherapy: analysis of a randomized, double-blind controlled trial. Support Care Cancer 27:1139\u20131147. https:\/\/doi.org\/10.1007\/s00520-018-4403-y","journal-title":"Support Care Cancer"},{"key":"4177_CR11","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.clpt.2005.08.015","volume":"78","author":"MO Babaoglu","year":"2005","unstructured":"Babaoglu MO, Bayar B, Aynacioglu AS, Kerb R, Abali H, Celik I et al (2005) Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists. Clin Pharmacol Ther 78:619\u2013626. https:\/\/doi.org\/10.1016\/j.clpt.2005.08.015","journal-title":"Clin Pharmacol Ther"},{"key":"4177_CR12","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1093\/jjco\/hyr117","volume":"41","author":"DA Perwitasari","year":"2011","unstructured":"Perwitasari DA, Wessels JA, van der Straaten RJ, Baak-Pablo RF, Mustofa M, Hakimi M et al (2011) Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy. Jpn J Clin Oncol 41:1168\u20131176. https:\/\/doi.org\/10.1093\/jjco\/hyr117","journal-title":"Jpn J Clin Oncol"},{"key":"4177_CR13","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2133\/dmpk.DMPK-12-RG-084","volume":"28","author":"D Tsuji","year":"2013","unstructured":"Tsuji D, Kim YI, Nakamichi H, Daimon T, Suwa K, Iwabe Y et al (2013) Association of ABCB1 polymorphisms with the antiemetic efficacy of granisetron plus dexamethasone in breast cancer patients. Drug Metab Pharmacokinet 28:299\u2013304. https:\/\/doi.org\/10.2133\/dmpk.DMPK-12-RG-084","journal-title":"Drug Metab Pharmacokinet"},{"key":"4177_CR14","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1016\/j.clinthera.2014.06.016","volume":"36","author":"H He","year":"2014","unstructured":"He H, Yin JY, Xu YJ, Li X, Zhang Y, Liu ZG et al (2014) Association of ABCB1 polymorphisms with the efficacy of ondansetron in chemotherapy-induced nausea and vomiting. Clin Ther 36:1242\u20131252. https:\/\/doi.org\/10.1016\/j.clinthera.2014.06.016","journal-title":"Clin Ther"},{"key":"4177_CR15","doi-asserted-by":"publisher","first-page":"102939","DOI":"10.1016\/j.critrevonc.2020.102939","volume":"149","author":"A Eliasen","year":"2020","unstructured":"Eliasen A, Dalhoff K, Mathiasen R, Schmiegelow K, Rechnitzer C, Schelde AB et al (2020) Pharmacogenetics of antiemetics for chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis. Crit Rev Oncol Hematol 149:102939. https:\/\/doi.org\/10.1016\/j.critrevonc.2020.102939","journal-title":"Crit Rev Oncol Hematol"},{"key":"4177_CR16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11096-010-9454-1","volume":"33","author":"DA Perwitasari","year":"2011","unstructured":"Perwitasari DA, Gelderblom H, Atthobari J, Mustofa M, Dwiprahasto I, Nortier JW et al (2011) Anti-emetic drugs in oncology: pharmacology and individualization by pharmacogenetics. Int J Clin Pharm 33:33\u201343. https:\/\/doi.org\/10.1007\/s11096-010-9454-1","journal-title":"Int J Clin Pharm"},{"key":"4177_CR17","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2217\/pgs.14.168","volume":"16","author":"S Sugino","year":"2015","unstructured":"Sugino S, Janicki PK (2015) Pharmacogenetics of chemotherapy-induced nausea. Pharmacogenomics 16:149\u2013160. https:\/\/doi.org\/10.2217\/pgs.14.168","journal-title":"Pharmacogenomics"},{"key":"4177_CR18","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1188\/16.ONF.389-393","volume":"43","author":"J Kiernan","year":"2016","unstructured":"Kiernan J (2016) Genetic Influence on Chemotherapy-Induced Nausea and Vomiting: A Narrative Review. Oncol Nurs Forum 43:389\u2013393. https:\/\/doi.org\/10.1188\/16.ONF.389-393","journal-title":"Oncol Nurs Forum"},{"key":"4177_CR19","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.critrevonc.2017.11.012","volume":"121","author":"KP Singh","year":"2018","unstructured":"Singh KP, Dhruva AA, Flowers E, Kober KM, Miaskowski C (2018) A review of the literature on the relationships between genetic polymorphisms and chemotherapy-induced nausea and vomiting. Crit Rev Oncol Hematol 121:51\u201361. https:\/\/doi.org\/10.1016\/j.critrevonc.2017.11.012","journal-title":"Crit Rev Oncol Hematol"},{"issue":"21","key":"4177_CR20","doi-asserted-by":"publisher","first-page":"4112","DOI":"10.1200\/JCO.2003.01.095","volume":"15","author":"PJ Hesketh","year":"2003","unstructured":"Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R et al (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin\u2013the Aprepitant Protocol 052 Study Group. J Clin Oncol 15(21):4112\u20134119. https:\/\/doi.org\/10.1200\/JCO.2003.01.095","journal-title":"J Clin Oncol"},{"key":"4177_CR21","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.1200\/JCO.2005.09.050","volume":"23","author":"DG Warr","year":"2005","unstructured":"Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD et al (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23:2822\u20132830. https:\/\/doi.org\/10.1200\/JCO.2005.09.050","journal-title":"J Clin Oncol"},{"key":"4177_CR22","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1093\/annonc\/mdl019","volume":"17","author":"HJ Schmoll","year":"2006","unstructured":"Schmoll HJ, Aapro MS, Poli-Bigelli S, Kim HK, Park K, Jordan K et al (2006) Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 17:1000\u20131006. https:\/\/doi.org\/10.1093\/annonc\/mdl019","journal-title":"Ann Oncol"},{"key":"4177_CR23","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1093\/oxfordjournals.aje.a112388","volume":"105","author":"AL Klatsky","year":"1977","unstructured":"Klatsky AL, Friedman GD, Siegelaub AB, G\u00e9rard MJ (1977) Alcohol consumption among white, black, or oriental men and women: Kaiser-Permanente multiphasic health examination data. Am J Epidemiol 105:311\u2013323. https:\/\/doi.org\/10.1093\/oxfordjournals.aje.a112388","journal-title":"Am J Epidemiol"},{"key":"4177_CR24","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1093\/annonc\/mdw220","volume":"27","author":"K Suzuki","year":"2016","unstructured":"Suzuki K, Yamanaka T, Hashimoto H, Shimada Y, Arata K, Matsui R et al (2016) Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study. Ann Oncol 27:1601\u20131606. https:\/\/doi.org\/10.1093\/annonc\/mdw220","journal-title":"Ann Oncol"},{"key":"4177_CR25","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1515725","volume":"375","author":"RM Navari","year":"2016","unstructured":"Navari RM, Qin R, Ruddy KJ, Liu H, Powell SF, Bajaj M et al (2016) Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med 375:134\u2013142. https:\/\/doi.org\/10.1056\/NEJMoa1515725","journal-title":"N Engl J Med"},{"key":"4177_CR26","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S1470-2045(19)30678-3","volume":"21","author":"H Hashimoto","year":"2020","unstructured":"Hashimoto H, Abe M, Tokuyama O, Mizutani H, Uchitomi Y, Yamaguchi T et al (2020) Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21:242\u2013249. https:\/\/doi.org\/10.1016\/S1470-2045(19)30678-3","journal-title":"Lancet Oncol"},{"key":"4177_CR27","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.breast.2020.01.005","volume":"50","author":"W Yeo","year":"2020","unstructured":"Yeo W, Lau TK, Li L, Lai KT, Pang E, Cheung M et al (2020) A randomized study of olanzapine-containing versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients. Breast 50:30\u201338. https:\/\/doi.org\/10.1016\/j.breast.2020.01.005","journal-title":"Breast"},{"key":"4177_CR28","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1111\/anae.1","volume":"70","author":"T Hayase","year":"2015","unstructured":"Hayase T, Sugino S, Moriya H, Yamakage M (2015) TACR1 gene polymorphism and sex differences in postoperative nausea and vomiting. Anaesthesia 70:1148\u20131159. https:\/\/doi.org\/10.1111\/anae.1","journal-title":"Anaesthesia"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-020-04177-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-020-04177-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-020-04177-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,23]],"date-time":"2021-10-23T19:09:53Z","timestamp":1635016193000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-020-04177-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,24]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["4177"],"URL":"https:\/\/doi.org\/10.1007\/s00280-020-04177-y","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,24]]},"assertion":[{"value":"20 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"D.T. reports personal fees from Nippon Kayaku Co., Ltd., personal fees from Chugai Pharmaceutical Co., Ltd., personal fees from Kyowa Hakko Kirin Co., Ltd., outside the submitted work, K.Y. reports personal fees from Sumitomo Dainippon Pharma Co., Ltd, personal fees from Kowa Pharmaceutical Co., Ltd., personal fees from DAIICHI SANKYO COMPANY, LIMITED, personal fees from Nippon Boehringer Ingelheim Co., Led, outside the submitted work, and H. N. reports personal fees from Yakult Honsha Co., Ltd, personal fees from Takeda Pharmaceutical Company Ltd., personal fees from AstraZeneca K.K., outside the submitted work;. All remaining authors have declared no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in accordance with Ethical Guidelines for Medical and Health Research Involving Human Subjects published by Japan\u2019s Ministry of Education, Culture, Sports, Science and Technology and the Ministry of Health, Labour and Welfare, Japan and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was approved by the institutional review board at Seirei Hamamatsu General Hospital.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}